mediworldme
www.mediworldme.com | November-December 2024

MEDIWORLD
Middle East

News & Update
Aspen Medical Collaborates with University of Wollongong in Dubai to Strengthen Healthcare Training Initiatives

Features
From Biologics to Breakthroughs: How UPS Healthcare Ensures Supply Chain Excellence

Features
How Clinique La Prairie is Transforming Longevity with Personalized Wellness Solutions

Features
Revolutionizing Patient Care: The Healthcare Vision of Prototypes for Humanity Humanity

Coverstory

Sheikh Shakhbout Medical City (SSMC)
Pioneering Excellence in Stroke and Cardiovascular Care

MEDiWORLD Middle East

Published Bi-Monthly: VOl 8 | Issue 6 | No. 46
Middle East, Africa, Asia & beyond

MediWorld ME aims to create the ultimate platform to share the latest news, updates & developments from the healthcare & medical technology industry within & beyond the GCC countries

• BAHRAIN • CYPRUS • IRAN • IRAQ • JORDAN • KUWAIT • LEBANON • OMAN • QATAR • SAUDI ARABIA • SYRIA • UNITED ARAB EMIRATES • YEMEN • ALGERIA • ANGOLA • BENIN • BOTSWANA • BURKINA FASO • BURUNDI • CAMEROON • CENTRAL AFRICAN REPUBLIC • CHAD • CONGO • COTE D'LVOIRE • DJIBOUTI • E.GUINEA • EGYPT • ERITREA • ETHIOPIA • GABON • GHANA • GUINEA • BISSAU • KENYA • LESOTHO • LIBERIA • LIBIYA • MADAGASCAR • MALAWI • MALI • MAURITANIA • MAURITIUS • MOROCCO • MOZAMBIQUE • NAMIBIA • NIGER • NIGERIA • RWANDA • SAO TOME & PRINCIPE • SENEGAL • SEYCHELLES • SIERRA LEONE • SOMALIA • SOUTH AFRICA • SUDAN • SWAZILAND • TANZANIA • TOGO • TUNISIA • UGANDA • ZAIRE • ZAMBIA • ZIMBABWE • BANGLADESH • BHUTAN • INDIA • PAKISTAN • SRI LANKA • NEPAL

7dimensions MEDIA FZE

PO Box: 9604, SAIF Zone, Sharjah - UAE
Tel: +971 6 557 9579, Fax: +971 6 579569,
info@7dimensionsmedia.com
www.7dimensionsmedia.com

EDITORIAL

The Quest for Longevity: Unlocking the Secrets to a Longer, Healthier Life

In recent years, the pursuit of longevity has evolved from a mere aspiration to a scientific endeavor. With advancements in medical science, biotechnology, and our understanding of aging, we are inching closer to unlocking the secrets of not just living longer, but living better. The quest for longevity is no longer limited to adding years to life; it's about adding life to years.

One of the most exciting developments in this field is the growing understanding of cellular aging and the role it plays in the diseases that shorten our lives. Scientists are increasingly focusing on the mechanisms that drive aging at the cellular level, such as telomere shortening, mitochondrial dysfunction, and the accumulation of senescent cells. By targeting these processes, researchers hope to slow down or even reverse aging-related decline. In fact, interventions like senolytics, which aim to remove dysfunctional, aging cells from the body, have shown promise in animal studies, leading to improved health and extended lifespan.

Another area of focus is caloric restriction and its effects on longevity. Studies have consistently shown that reducing caloric intake without malnutrition can extend the lifespan of various species, from yeast to primates. While human trials are ongoing, the potential for dietary interventions to promote healthspan—the period of life spent in good health—could revolutionize aging research.

Beyond genetics and lifestyle changes, advancements in regenerative medicine, particularly stem cell therapies, are showing potential for treating age-related conditions. Whether it's using stem cells to repair damaged tissues or developing therapies to regenerate organs, regenerative medicine could offer groundbreaking solutions for maintaining vitality as we age.

As we continue to explore the science behind aging, it's clear that longevity is no longer just about extending life; it's about enhancing the quality of those extended years. The future of healthcare is a world where aging gracefully is within our reach.

Laique Khan,
Editor

WORLDWIDE MEDIA REPRESENTATIVES
France, Belgium, Monaco, Spain: Aidmedia, Gerard Lecoeur;
Tel: +33 (0) 466 326 106; Fax: +33 (0) 466 327 073
India: RMA media, Faredoon Kuka;
Tel: +91 22 5570 3081; Fax: +91 22 5570 3082
Taiwan: Advance Media Services Ltd, Keith Lee;
Tel: (886) 2 2523 8268; Fax: (886) 2 2521 4456
Thailand: Trade and Logistics Siam Ltd, Dwight A Chiavetta;
Tel: +66 (0) 2650 8690; Fax: +66 (0) 2650 8696
UK, Ireland, Germany. Swizerland, Austria: Horseshoe Media,
Peter Patterson; Tel: +44 208 6874 160

CONTENTS

Sheikh Shakhbout Medical City (SSMC):
Pioneering Excellence in Stroke and Cardiovascular Care

By: Laique Khan

In an exclusive interview, Dr. Isam Sayed Mahmoud Salih, a leading vascular neurology consultant at Sheikh Shakhbout Medical City, discusses the institution's pioneering role in stroke and cardiovascular care, its adoption of groundbreaking technologies, and its vision for advancing global medical excellence.

Nestled in the heart of Abu Dhabi, Sheikh Shakhbout Medical City (SSMC) stands as a leading institution in advanced medical care and innovation.

With a deep-rooted commitment to excellence, SSMC has garnered global recognition, particularly for its comprehensive stroke and cardiovascular care.

Dr. Isam Sayed Mahmoud Salih, a vascular neurology consultant, chairs the Neurology Division and directs the Stroke Division at SSMC.

With his expertise and the institution's unwavering commitment to patient care, SSMC continues to set benchmarks in medical excellence.

In this interview, Dr. Isam Sayed Mahmoud Salih sheds light on the institution's transformative journey, groundbreaking technologies, and vision for the future.

Recognition as a Catalyst for Patient Trust

The recognition of SSMC as a Comprehensive Stroke Center by the American Heart Association and its accreditation as a Centre of Excellence by the Department of Health – Abu Dhabi has profoundly bolstered patient trust. These accolades, according to Dr. Salih, are more than just acknowledgments; they signify adherence to the highest standards of care.

"Patients see these recognitions as assurances that they will receive quality and efficient care for complex conditions," he explains. Central to this trust is the establishment of a 24/7, state-of-the-art stroke unit. Staffed by specialized medical professionals and equipped with advanced diagnostic tools, the unit exemplifies SSMC's dedication to innovative and comprehensive stroke care.

The availability of cutting-edge treatments and highly trained experts strengthens confidence among patients and their families. Knowing that SSMC's medical team is equipped to handle the most challenging cases fosters an environment of trust and reassurance, making SSMC a preferred choice for critical stroke care.

Advanced Technologies: A Leap Forward in Patient Outcomes

SSMC's investment in advanced technologies is setting new benchmarks in medical care. In June 2022, the hospital launched the Biplane Angio Suite, a revolutionary facility enabling multidisciplinary teams to perform urgent angiograms and mechanical thrombectomies. This innovation is instrumental in rapidly identifying and removing blood clots in ischemic stroke patients.

"Timely intervention is critical," Dr. Salih emphasizes. "Restoring blood flow to the brain quickly significantly improves long-term outcomes."

Complementing the Angio Suite is the Philips Azurion 7 B20/15 biplane image-guided therapy system, which enhances the precision of interventions. Additionally, advanced neuroimaging tools such as CTA, MRI/MRA, and perfusion scans enable early diagnosis and tailored treatment plans.

SSMC also boasts specialized neurocritical beds and advanced monitoring devices, ensuring patients receive immediate, high-quality care. "These technologies not only improve patient outcomes but also elevate the overall experience by delivering personalized and effective treatments," says Dr. Salih.

Swift and Coordinated Stroke Care

The cornerstone of SSMC's stroke care is its emphasis on speed and precision. The Biplane Angio Suite plays a pivotal role in ensuring rapid diagnosis and intervention.

"Stroke is a race against time," Dr. Salih notes. "Our protocols are designed to act swiftly and minimize brain damage."

Specialized multidisciplinary teams work in harmony, streamlining the process from diagnosis to treatment. This coordination ensures that every aspect of stroke care is executed efficiently. By leveraging advanced tools and maintaining a highly trained staff, SSMC minimizes delays and enhances the quality of care, ultimately improving patient outcomes.

Academic Collaborations: Shaping the Future of Healthcare

SSMC's vision extends beyond immediate patient care; it is deeply invested in shaping the future of healthcare. Its robust academic structures,

Isam Sayed Mahmoud Salih
Vascular Neurology consultant
Sheikh Shakhbout Medical City

symbolized by the 'Education Shield,' foster continuous learning and collaboration among healthcare professionals.

"We believe in developing new experts to carry forward SSMC's legacy," Dr. Salih shares. This mission is supported by five educational centers that host various initiatives, ensuring staff are well-versed in the latest medical advancements.

A standout initiative is the Centre of Medical Innovation and Simulation. This facility provides advanced simulation training, offering realistic clinical scenarios that enhance the skills and knowledge of healthcare professionals. By prioritizing education and training, SSMC not only improves its internal capabilities but also contributes to the global medical community by nurturing well-trained experts.

Supporting International Patients and Innovating for the Future

SSMC's reputation extends far beyond the UAE, attracting international patients seeking specialized care. One of its groundbreaking initiatives is the study of innovative rehabilitation strategies using a novel device suit for stroke patients. These studies aim to enhance mobility, reduce pain, and improve treatment decisions," Dr. Salih explains.

These advancements underline SSMC's dedication to staying at the forefront of medical innovation. By continuously enhancing its services and integrating new technologies, SSMC reaffirms its position as a leader in global healthcare.

A Legacy of Excellence

Sheikh Shakhbout Medical City is not only a medical facility; it is a hub of innovation and excellence. With a strong foundation in advanced technologies, academic collaboration, and patient-centered care, SSMC is setting new benchmarks in stroke and cardiovascular care, ensuring that patients receive the best possible outcomes, no matter where they come from.

SSMC's journey is a testament to its unwavering commitment to excellence in healthcare. From earning prestigious recognitions to adopting groundbreaking technologies and fostering a culture of continuous learning, SSMC exemplifies what it means to lead in modern medicine. Under the guidance of experts like Dr. Isam Sayed Mahmoud Salih, SSMC continues to redefine healthcare standards, offering hope and healing to patients from around the world.

From Biologics to Breakthroughs: How UPS Healthcare Ensures Supply Chain Excellence

By: Laique Khan

Wanis El Kabbaj
Senior Director
Global Marketing
UPS Healthcare

In this exclusive interview, learn how UPS Healthcare's investments in robotics, track-and-trace solutions, and digital platforms are setting new standards in healthcare logistics.

As we navigate the complex world of healthcare, it's easy to overlook the intricate logistics that make everything possible.

Behind the scenes, there's a carefully coordinated effort to ensure that temperature-sensitive medications, life-saving medical devices and critical healthcare products are delivered safely and on time.

For many, these deliveries are a matter of life and death.

In this interview, Wanis El Kabbaj, Senior Director of Global Marketing at UPS Healthcare, discusses the transformative power of logistics in healthcare.

He explains how UPS Healthcare is leading the charge in revolutionizing healthcare supply chains, making sure that crucial medical goods reach their destinations securely and efficiently.

El Kabbaj highlights the unsung heroes of healthcare logistics, those who ensure that life-saving drugs and fragile medical devices arrive where they are needed.

With UPS Healthcare's innovative solutions, cutting-edge technology and commitment to precision, the company is playing a key role in shaping the future of healthcare logistics.

How does UPS Healthcare differentiate itself in the highly competitive logistics and supply chain market, particularly in serving healthcare clients?

When you look to the future of healthcare, it's all about innovations in biologics, specialty pharmaceuticals, and personalized medicine – to help support aging populations and manage problems related to chronic disease.

55% of the drugs in the development pipeline are biologics.

When biologics are involved, cold chain and temperature monitoring services are needed.

These products make up most of the new products in development and is driving significant demand for precision logistics.

We've been investing to meet the needs of this growing and evolving market for a long time, building out a 'network within a network' to make sure we provide the best quality, end-to-end service on the market for healthcare shippers that are at the forefront of innovation.

These investments include advanced technologies like robotics, automated picking systems, and track-and-trace solutions have a vital role as they help streamline order fulfillment, reduce errors, increase efficiency, and ensure continued regulatory compliance.

If a customer is looking for someone to manage everything from clinical to commercial, we are really the only solution that can take care of the full, end-to-end supply chain.

Managing temperature - sensitive shipments is critical in healthcare logistics. How does UPS Healthcare ensure the integrity and reliability of such deliveries?

The need for cold-chain infrastructure, real-time visibility, location and temperature intervention during disruptions; it's critical to have these things in place.

Rapid advances in digital technology create opportunities to optimize almost every aspect of the supply chain, from production to delivery.

You can create a comprehensive data stream from pick-up to delivery that makes a supply chain 'smarter' and, by extension, more resilient – especially if one area were to experience delays. However, harnessing real-time data is only one-half of the equation. Being able to act on this data – having 'control' – is the other.

Now this can all sound abstract, but when you consider even 0.5% of pharma shipments impacted or spoiled by temperature can incur substantial costs (in the millions) – not to mention affect patients – we can see how important the underpinning of physical and software-based digital infrastructure is.

Whether it's in response to weather, geopolitical issues, or the need to re-route time-sensitive, high-

value shipments there is an urgent need to combine digital and physical networks.

The best logistics partners can provide a 'control tower' overview of an entire supply chain. Through both visibility and control, the digital and the physical can reveal many ways to improve collaboration and efficiency that lead to smart, fast, sustainable decisions based on real-time data instead of guesswork.

Perhaps most importantly this is also indicative of a shift from reactive to proactive based on the predictive powers of these technologies.

alone isn't enough—coordination and orchestration of processes across departments are critical to fully harness its benefits.

To tie everything together, we have recently introduced the UPS Supply Chain Symphony™ platform. It is a new tool that integrates various supply chain components, including shipping, warehousing, and inventory management, into a single platform. This unified approach empowers UPS customers to operate more efficiently, gain better visibility into their supply chains, and more effectively address challenges as they arise.

How does UPS Healthcare's use of advanced track-and-trace solutions, such as UPS Premier and the new Supply Chain Symphony™ platform, enhance visibility and coordination across the supply chain, and what impact does this have on overall efficiency and resilience?

Track-and-trace solutions, like our very own UPS Premier, are also becoming so advanced they can now log humidity, light exposure and a series of other metrics, allowing them to be easily rerouted and located anywhere globally to within 3 meters thanks to mobile technology.

We call it orchestration, with a supply chain powered by technology that makes our networks more seamless, adaptable, and resilient. Technology

What strategies does UPS Healthcare employ to maintain compliance with global regulations for medical and pharmaceutical deliveries?

Complex healthcare shipments are some of the most heavily regulated in the world, requiring temperature monitoring, quality documentation through a chain of custody and have tight handling needs and expiration dates.

You must be very good at understanding regulation and enabling audit defensibility for your customers, all underpinned by a culture of service. After all, it's patients who matter the most.

We have hundreds of people worldwide whose sole focus is on quality assurance – that's how important it is for us.

UPS Healthcare supports logistics for both large healthcare systems and smaller clinics. How do you tailor your solutions to meet the unique needs of different types of clients?

These shipments are some of the most sensitive in the world, and necessary temperature and visibility control remain an issue for many. The need for cold-chain infrastructure, real-time visibility and location, temperature intervention during disruptions, it's critical to have these things in place to properly execute along the supply chain.

But you don't just stockpile these solutions on a shelf. It is not a one-size-fits-all solution. These are one-size-fits-one solutions. Which means the supply chain needs to be significantly different and rely on a multi modal logistics network that can adapt to our customers and their patient's needs.

Can you discuss any recent partnerships, initiatives, or investments in the Middle East that are enhancing your footprint and services in the region?

We're investing more than a billion dollars from 2024 through 2026 to expand our global footprint.

Thanks to our integrated, multimodal network, the Middle East's leading pharmaceutical, medical device, and laboratory companies will have access to new and traditional markets.

Looking ahead, what key trends do you foresee shaping the future of healthcare logistics, and how is UPS Healthcare preparing for them?

Everyone has seen the major advances in AI, and we should expect it to play an increasing role in supply chain management. It can analyze weather, traffic, and predict delays even before they happen and it allows us to optimize routes, reduce driver time, reducing fuel consumption, and be more accurate with delivery window times all optimizing order management.

We also expect to see continued growth in home health, whether that's telemedicine, diagnostics or delivery of treatments. There are many benefits of taking treatment out of hospitals and facilities if it's not needed, but it requires a shift in supply chains and particularly how we deliver these time and temperature sensitive products in the last mile.

These shifts will require even better orchestration of our physical and digital assets, but thankfully our work with the healthcare industry has so far provided a very good roadmap for leveraging technology in critical supply chain sectors and how it can be adapted for digitization.

And if we work to this level of precision for these products and industries – then why not others?

How Clinique La Prairie is Transforming Longevity with Personalized Wellness Solutions

By: Laique Khan

Simone Gibertoni, CEO of Clinique La Prairie, shares insights on the brand's 90-year legacy in longevity, the launch of their Longevity Fund, and the groundbreaking Dubai Longevity Hub, blending cutting-edge science, personalized therapies and wellness to redefine health and vitality.

Lifelong health isn't just about adding years to your life, it's about enhancing the quality of those years.

Having pioneered this field for 90 years, Clinique La Prairie (CLP) is at the forefront of this innovative revolution.

With their Longevity Fund and Dubai Longevity Hub, Clinique La Prairie redefines health and vitality through advanced diagnostics, personalized therapies and holistic wellness.

CLP's pioneering efforts are creating ripple effects in the global wellness economy, whether it's addressing cellular aging or boosting mental resilience.

Longevity is a key and rapidly growing component of the global wellness economy, which was valued at USD 5.6 trillion in 2022. The global longevity economy alone is projected to reach approximately USD 610 billion by 2025 (Global Wellness Summit 2024).

Simone Gibertoni, CEO of Clinique La Prairie, discusses the groundbreaking synergy between science, wellness and technology behind the Longevity Fund.

Clinique La Prairie has launched a Longevity Fund aimed at enhancing healthspan and lifespan innovations. Could you tell us more about the inspiration behind this initiative and its main objectives?

The launch of the Longevity Fund reflects Clinique La Prairie's strategic commitment to driving forward the science and future of longevity – an area we have pioneered for over 90 years.

The fund is an initiative in collaboration with Prof. Stefan Catsicas and his seasoned team, structured to support projects and companies that drive innovation in next-generation health and wellness technologies, while providing investors with the opportunity to participate in a transformative shift within these industries.

CLP has recently expanded into Dubai with the Longevity Hub. What inspired this expansion, and how does it align with your global mission for health and longevity?

Expanding into Dubai with the Longevity Hub is a pivotal step in Clinique La Prairie's strategy to bring its longevity expertise to new regions, allowing clients to integrate longevity practices into their daily lives, closer to home. It is the first of its kind, offering an exclusive approach. In the luxurious three-story setting of One & Only One Za'abeel, it provides ultra-personalized health journeys, beginning with unique Longevity Assessments. With pioneering therapies—from Senaptec brain & movement analysis and cryotherapy to IV drips and infrared detoxification —the Hub combines cutting-edge science with tailored solutions. Year-round membership programs offer comprehensive benefits for a truly transformative journey.

The Hub serves as a center for delivering CLP's longevity approach to self-care and performance

optimization, inside-out, with guidance from CLP experts.

The concept of longevity goes beyond just extending lifespan—it focuses on enhancing the quality of life. How does CLP's approach differentiate itself in terms of integrating wellness, science, and advanced technology?

Yes, exactly, longevity means both, healthspan and lifespan. At Clinique La Prairie's destinations, the goal is to help clients live fuller and healthier (this is our primary objective), and also to live longer. This speaks to the difference between healthspan and lifespan.

We do it by combining advanced diagnostics, cutting-edge treatments, and personalized therapies to address aging holistically. It's what we call our CLP Longevity Method. Diagnostics are fundamental today because they not only allow us to anticipate (prevent) but also to tailor treatments. From simpler diagnostics like blood tests or X-rays to more complex ones—genetic, epigenetic, microbiota, glycans tests.

How does Clinique La Prairie's Four Pillars approach—Medical, Nutrition, Wellbeing and Movement integrate advanced science and personalized therapies to optimize longevity and healthspan?

At Clinique La Prairie, we've divided this approach into what we call the Four Pillars: Medical, Nutrition,

Wellbeing, and Movement. This structure helps clients understand the importance of a holistic approach to longevity, and also provides clear research categories for our team and an effective way to balance our programs. While all pillars are important, we place particular emphasis on the medical aspect.

The Nutrition Pillar includes 4-D advanced nutritional assessment, personalized nutrition therapy under CLP Method and longevity nutraceutical solutions. In the Wellbeing Pillar, we implement methodologies and technologies—some of which are exceptionally innovative—to reduce chronic stress and empower mental and cognitive health. Finally, in the Movement Pillar, we use the science of Sports Medicine to give a strong scientific angle with simple, personalized, and actionable protocols.

What are the Longevity Fund's contributions to innovation in health care, nutrition, movement, and wellbeing?

As for the Longevity Fund itself, the structure also enables us to push boundaries over the long term. We align our investment strategy with four pillars: Medical Care, Nutrition, Movement, and Wellbeing. The fund supports entrepreneurs and researchers in these areas so they can develop innovative approaches to chronic inflammation, immune resilience, and cellular aging. New wellbeing ideas might focus on mental health and sleep quality; innovation in nutrition may focus on functional foods and AI-driven personalized nutrition; and movement innovations may focus on customizing exercise technologies.

By embracing this ecosystem vision, we are positioned to drive global advancements in longevity and healthcare.

Can you provide insights into the collaborative efforts or partnerships CLP has formed through its Longevity Fund to drive innovation?

We have formed a strategic partnership with Prof. Stefan Catsicas, one of the world's foremost experts in longevity. Prof. Catsicas brings extensive experience in cell biology, having served as Professor and Chairman at the Lausanne School of Medicine and as Vice President of Research at the EPFL in Switzerland.

As a co-founder and advisor to several biotechnology firms and investment funds, Prof. Catsicas possesses a deep understanding of both biotechnology and large-scale investments. His role as Co-Chair of the Investment Committee and Investment Advisory at the Longevity Fund structure will leverage his expertise in advisory and investment strategy, making him an invaluable partner in shaping and guiding the fund's strategic direction.

The primary goal of the fund is to accelerate innovation in longevity science by supporting projects that move beyond the exploratory research phase toward practical applications.

The Fund structure will focus on backing businesses that can bring scientifically-grounded, commercially viable solutions to market, for real-world impact. Our emphasis is on funding ventures that translate longevity research into tangible, scalable products and services that can improve human health and lifespan.

Looking forward, what are CLP's plans for advancing the field of longevity science, how would you define the long-term vision for Clinique La Prairie in the context of global longevity and healthcare advancements?

In Clinique La Prairie's long-term vision, innovation remains foundational. This commitment is supported by our in-house experts and by our collaborations with internationally renowned scientists on our Scientific Committee, who bring extensive insights on longevity and precision medicine, including areas like senescence, genetics, brain health, nutrigenomics, immunology, epigenetics, cell biology (just to name few), to consistently enhance our offerings.

In the future, we will develop further age-related diagnostics, nutrition approaches, or latest wellness technologies. Also, today, precision medicine is powered by predictive systems driven by AI and machine learning, allowing early detection of health shifts even in "silent mode." By identifying subtle changes in the body, these systems enable targeted interventions to prevent disease progression and enhance longevity, empowering both doctors and patients. This transformative approach will continue shaping our method and offering.



Revolutionizing Patient Care: The Healthcare Vision of Prototypes for Humanity

By: Laique Khan

Tadeu Baldani Caravieri discusses AI-driven diagnostics, wearable health devices and advanced cancer therapies in this exclusive interview.

As the founder director of Prototypes for Humanity, Tadeu Baldani Caravieri has championed a platform that connects academic talent with industry expertise.

As a flagship initiative of the Dubai Future Foundation, Prototypes for Humanity displays groundbreaking innovations from more than 800 universities worldwide, including Stanford University, MIT and Cambridge University.

The initiative, now in its 10th year, aims to improve healthcare, sustainability and societal wellbeing.

During this conversation, Tadeu highlights the potential for healthcare-focused projects in the program.

One of this year's standout innovations is 'Angie', a unique CAR T-cell delivery system that targets brain stem gliomas, and 'Peter', a wearable device that helps Parkinson's patients.

Additionally, the program addresses pressing global healthcare challenges, from antimicrobial resistance to affordable diagnostics.

In order to accelerate the path from prototype to scalable solution, the initiative facilitates partnerships with government, industry and investors.

Its impact can be seen in projects such as Dermopsy, which uses artificial intelligence to diagnose skin diseases, and Horseshoe Imaging, which provides ultrasounds to remote areas at a low cost.

A healthcare-focused organization, Prototypes for Humanity is fostering accessibility and enhancing patient outcomes.

What inspired the focus on health solutions within Dubai Future Solutions – Prototypes for Humanity, and how do you see these innovations reshaping global healthcare?

Academia is a global catalyst for innovation and Dubai Future Solutions – Prototypes for Humanity brings together thousands of the brightest young minds from across the world with solutions for challenges the planet and society are facing today. This year, we had thousands of entries from over 800 universities, including Stanford, Oxford, Cambridge and MIT and we invited 100 exceptional innovators to Dubai for the annual exhibition.

Healthcare is a major component each year and we had over than 30 ground-breaking projects from students and recent graduates in the 100 shortlisted projects for this year's programme. These included a prototype device to help people with Parkinson's disease walk again from the University of Cambridge, an AI-enabled camera-solution to log daily actions for people with memory impairment and more targeted cancer-treatment therapies.

Whether addressing global risks or localized problems, these shortlisted projects propose tangible ways forward, backed by research and driven by vision and entrepreneurial spirit.

Can you elaborate on the key healthcare challenges that Dubai Future Solutions - Prototypes for Humanity is addressing through its platform?

This year's projects all aim to solve pressing issues in diagnostics, disease prevention, and personalized care. Innovations range from AI-powered diagnostic tools, wearable health monitoring devices, and targeted drug delivery systems, to accessible and efficient health solutions for marginalized groups. Collectively, they aim to enhance patient outcomes, reduce healthcare costs, and improve the quality of life for diverse populations globally.

With healthcare being one of your priority areas, what are some of the most groundbreaking projects you've encountered through the program?

The award recipient in the health category this year was Fabian Landers from ETH Zurich, Switzerland, with his innovation 'Angie', which helps treat people with inoperable brainstem gliomas, which are resistant to conventional therapies. Fabian has developed a solution involving magnetically guided microcapsules that deliver CAR T-cells directly to the tumor site. Using remote magnetic navigation and ultrasound-triggered release, the precise delivery system enhances the efficacy of CAR T-cell therapy while minimizing side effects. This breakthrough approach offers hope for improving survival rates in patients suffering from this aggressive cancer.

Jon Fisher from the University of Cambridge was driven by his father's experience with Parkinson's diseases and has designed a solution he called 'Peter' – after his father.

'Peter' is a wearable biomedical device that helps people with the disease overcome a temporary freezing in their legs, a debilitation that prevents movement. Using AI and real-time tracking, the device detects when the legs stop working and plays rhythmic signals through the collarbone using bone conduction. This rhythm, only audible to the user, helps the person regain movement without drawing attention.

How does Dubai Future Solutions-Prototypes for Humanity collaborate with academic institutions to address pressing healthcare challenges like diagnostics, disease prevention, and patient care? What role does the healthcare section of the program play in tackling global issues such as antimicrobial resistance and affordable diagnostics in underserved communities?

Over the past decade, my team and I have established the world's largest network of academic talent working on solutions for complex global issues, uniting over 20,000 professors from more than 800 universities across 6 continents. Each year we invite students and graduates to submit innovations that will help tackle pressing concerns in healthcare, alongside urgent challenges relating to energy, materials, environment, data and agriculture.

The core of Dubai Future Solutions – Prototypes for Humanity initiative is offering innovators the opportunity to scale their ideas and access crucial industry, government and investor partnerships to make their ideas a reality. We do this through a dedicated programme focusing on Dubai-based technology and commercial pilots with leading organizations. With industry partnerships, we help propel the ideas forward and develop them into viable, commercial ventures that can be developed at scale.

Some examples from this year's cohort include AmCURE Antibiotic, a targeted antimicrobial treatment for resistant infections. Antimicrobial resistance (AMR) poses a grave risk, potentially ushering in a 'post-antibiotic era' where even minor infections could become deadly. Traditional

antibiotics are losing efficacy, and new alternatives, like cationic polymers, show promise but face issues with in vivo toxicity. Developed by Bo Zhang from Nanyang Technological University in Singapore, AmCURE Antibiotic addresses this by employing a "caging" strategy, where antimicrobials are deactivated and safely contained until reaching the infection site. This method releases the antimicrobials only in the presence of specific bacterial enzymes, reducing toxicity and enhancing treatment efficacy.

Your work with Horseshoe Imaging aims to make diagnostic ultrasound more accessible in low-income and remote areas. Could you elaborate on how the silicone-encapsulated probe and real-time data processing technologies make this innovation both cost-effective and portable for practical use in such settings?

Developed by Nisal Jayaneththi from The University of Melbourne, Horseshoe Imaging addresses the need for accessible diagnostic ultrasound in low-income and remote areas. Unlike traditional, expensive ultrasound equipment used only in clinical settings, this system features a flexible, silicone-encapsulated probe that conforms to the skin and simplifies manufacturing.

This innovation offers accessible diagnostic ultrasound for low-income and remote areas by offering a low-cost, portable wearable system. The system includes a compact electronic unit with an FPGA and Arm Processor for real-time data processing and streaming. This innovation enables continuous monitoring for applications like prenatal care, cardiac evaluation, and sports biomechanics, making high-quality imaging accessible and practical in various settings.

Dermopsy integrates Generative AI and deep learning with reflectance confocal microscopy to revolutionize dermatological diagnostics. How does the virtual staining process improve the speed and accuracy of diagnosing skin disorders compared to traditional histological methods?

Traditional methods for diagnosing skin disorders, including cancer and fungal infections, are often slow, costly, and invasive. Mashaal Ibne Masha Allah from the National University of Sciences & Technology (NUST), has found a solution, Dermopsy, which utilizes a reflectance confocal microscope combined with advanced Generative AI and deep learning techniques to provide rapid, non- invasive diagnosis. This system performs virtual staining and segments infection samples without the need for traditional histological stains, reducing diagnostic time from days to minutes and lowering costs. Integrated on a cloud platform, it enables dermatopathologists to make swift, accurate decisions, significantly improving patient outcomes.

AiSee is an excellent example of technology addressing disabilities. How do you select and prioritize projects that focus on inclusivity and improving the quality of life for marginalized communities?

Drawn from thousands of applications from more than 800 universities, from over 100 countries around the world, these 100 exceptional innovations cover areas from health, data and society to energy and nature. Whether addressing global risks or localized problems, we felt these shortlisted 100 projects propose tangible ways forward, backed by research and driven by vision and entrepreneurial spirit.

The winners were selected from a panel of prominent judges, who are all experts in their field and provide valuable insight across a range of industries and professions:

- Her Highness Sheikha Latifa bint Mohammed bin Rashid Al Maktoum, Chairperson of the Dubai Culture and Arts Authority (Dubai Culture)
- Khalfan Belhoul, CEO of the Dubai Future Foundation (DFF)
- Kristoffer Gandrup-Marino, Chief of Innovation, UNICEF
- Naren Barfield, professor Emeritus, former Deputy Vice-Chancellor and Provost at the Royal College of Art
- Amira Sajwani, Managing Director at DAMAC Properties
- Lauren Selig, Entrepreneur, Investor and Philanthropist

The five winners share between them an AED 360,000 prize pool to further advance their research in critical areas.

How does Dubai Future Solutions - Prototypes for Humanity ensure that healthcare innovations from your platform reach communities in need?

Bringing together the best minds in academia, Dubai Future Solutions - Prototypes for Humanity reflects the current state of innovation and how complex issues are manifested, and addressed, by top academic talent.

Students and recent graduates are able to interact with industry professionals much faster than in the past due to the initiative, which gives visibility to innovations. During the four-day exhibition, we gather 100 exceptional innovators from across the world, along with industry professionals, government representatives, and investors, forming the world's largest network of academic talent. It allows students and recent graduates to access investor partnerships that will enable them to take their ideas to the next level.

What kind of support does Dubai Future Solutions - Prototypes for Humanity offer healthcare innovators in terms of funding and venture-building?

We work with experts in their relative fields and the 2024 exhibition programme included a series of curated roundtables, connecting participants with leading public and private entities with a view to supporting their growth through venture-building.

Our program continues long after the exhibition has ended, as we provide ongoing support to participants with access to government, industry and investor partnerships so their innovations can be developed further.

Dubai Future Solutions - Prototypes for Humanity has had a positive impact on global healthcare solutions and innovation through its presence in UAE. How has it done this?

In 2024, Art Dubai Group and Dubai Future Foundation (DFF) created the Dubai Future Solutions - Prototypes for Humanity program, marking the 10th anniversary of the Prototypes for Humanity community's creation. This year's exhibition took place during the Dubai Future Forum of the Dubai Future Foundation. Designed to foster innovation, Dubai Future Solutions - Prototypes for Humanity showcases Dubai's commitment to fostering breakthrough ideas and its commitment to supporting the dreams of young people from around the world.

We received 11 pilot models from the Middle East and four from the United Arab Emirates. It's exciting to see the energy and excitement of young people. Using their talents, they hope to positively impact future generations. From climate change to new diseases to food security to ageing populations, we see a strong motivation among talented students to help change these conditions.

In the next 5-7 years, how do you envision Prototypes for Humanity's healthcare section growing? What does it mean for global healthcare innovation?

Based on the applications that we receive from students and recent graduates, the program aims to reflect academic innovation globally.

Our mission is to showcase and support healthcare projects that illustrate what's on the minds of international graduates across all disciplines. In the coming years, AI combined with efforts to democratize diagnosis will continue to play a very prominent role, alongside pharmaceutical solutions. Through robust POC and piloting opportunities, we will leverage Dubai's healthcare infrastructure as well as the willingness of public and private stakeholders to embrace innovation.

How Value-Based Care can improve Healthcare Outcomes - and why it works

Globally, the healthcare industry is at a turning point.

The rising costs of healthcare, aging demographics and the need to address disparities in access and outcomes challenge healthcare systems worldwide.

In the future, how healthcare is managed, delivered, funded and spent will profoundly depend on what direction the sector takes today.

Value-based care (VBC) is an opportunity to reshape global healthcare management, delivery, and funding while changing lives for the better as a way to address all of these challenges.

What is value-based care, and why do healthcare organizations need to invest in the infrastructure that makes it successful?

By its very nature, VBC represents a paradigm shift from volume-based models that compensate providers for services provided to outcomes-based models. In this system, the focus shifts away from the quantity of services delivered - office visits, diagnostic tests, procedures - to the quality of the results. Prioritizing wellness, prevention and person-centered care over profit-driven volume is at the heart of the program.

Incentives at VBC are aligned with wellness, prevention and effective management of chronic illnesses to maximize the impact of every dollar spent. In other words, it rewards healthcare providers for doing more rather than more well.

A 'Value-Based' Promise

VBC is more than a theoretical concept, it is a practical approach based on measurable results. The goal is to enhance the delivery of healthcare by ensuring that the right care is delivered at the right time by the right provider in the right setting.

To take meaningful steps toward managing long-term health outcomes rather than merely responding to acute episodes, healthcare organizations should transition from reactive to proactive care. A proactive approach, timely interventions, and seamless transitions of care can reduce emergency room visits, hospital readmissions and financial costs.

While VBC has great potential, uptake has been very slow. Often, healthcare organizations encounter obstacles like misaligned incentives, fragmented care delivery systems, and reluctance to change when transitioning from fee-for-service/volume-based payment models.

Efficacious implementation of VBC requires more than just a conceptual concept; it requires rethinking longstanding structures and processes, including fundamental changes in healthcare delivery, management, and financing.

As a result, we believe that VBC requires fundamental changes across three domains: clinical and service delivery, operational processes, and performance management and compliance.

VBC and clinical delivery

A better coordination of services is the first step toward realizing the potential of VBC. As part of this effort, seamless pathways should be created between hospitals, clinics, and social services to address not only medical requirements, but also broader social factors affecting health, such as housing, transportation, and access to nutrition.

Risk stratification is a crucial element of managing chronic diseases - a core aspect of VBC - so that high-need patients can be identified and treated effectively.

Despite the importance of provider engagement, only 23 percent of Care Allies-Modern Healthcare Survey participants said their VBC strategy is well-understood by physicians.

For value-based care to be adopted by physicians and other stakeholders, compensation structures must be redesigned. Rather than rewarding larger service volumes, alternative payment models (APMs) reward efficiency and better outcomes. Financial incentives can be aligned with improvements in care quality through APMs, which include shared savings initiatives and population-based payment plans.

A key component of service coordination is communication. VBC requires physicians to understand why it exists, but also their roles, responsibilities and rewards.

The role of operational excellence

Information technology is a key enabler of VBC.

Interoperable electronic health records, patient portals, and remote monitoring tools enable healthcare providers to track patient data in real time, making personalized care possible. Artificial intelligence and machine learning amplify this capability by uncovering patterns and insights that would otherwise be overlooked.

Through advanced analytics - enhanced by artificial intelligence applications - high-risk patients can be identified early, so proactive interventions can be made before costly health crises occur. Likewise, real-time data analysis enables care teams to monitor treatment outcomes.

The importance of patient engagement cannot be overstated.

To achieve VBC, patients must change their perception of their roles in their own care - from passive recipients to active participants.

Telehealth systems, mobile apps and remote monitoring devices are essential tools for promoting lifestyle changes, improving compliance with treatment, and reducing unnecessary hospital admissions.

Annie Mayol
Senior Managing Director, FTI Consulting

Georges Assy
Senior Managing Director, FTI Consulting



Juan Montañez
Senior Managing Director, FTI Consulting

Monitoring and managing compliance and performance

As a result of VBC adoption, providers are also faced with new financial challenges. Financial risk management and incentivizing outcomes must be balanced by organizations.

Instead of seeing this as a disadvantage, it should be viewed as an opportunity. Taking greater responsibility for healthcare costs can help providers make more effective decisions for their patients.

However, to effectively manage risk within a VBC framework, planning and preparation are crucial. Using data-driven modeling, actuaries can assist organizations in developing sustainable pricing models, allocating reserves, and projecting long-term financial performance.

Compliance with regulatory requirements is also crucial.

The complexity of VBC payment systems must be managed with strong compliance frameworks while maintaining transparency and trust.

A road map for the future

It might be challenging to achieve broad VBC adoption, but the benefits outweigh the challenges. Rather than merely seeing it as another passing trend, healthcare organizations should view it as necessary evolution. In a changing landscape, in which efficiency, outcomes, and patient experience are paramount, those who hesitate risk falling behind.

A clear call to action for healthcare leaders is to embrace value in order to embrace the future. To provide better care to everyone, healthcare organizations should focus on outcomes rather than volume and sustainable business practices rather than short-term profits.

Investment in technology, promoting integration and aligning incentives with outcomes may be complex steps toward establishing the appropriate infrastructure.

Life is improved and costs are reduced, so the rewards are more than worth the effort.

Opinion provided by: FTI Consulting

Authors:

- Annie Mayol, Senior Managing Director, FTI Consulting
- Juan Montañez, Senior Managing Director, FTI Consulting
- Georges Assy, Senior Managing Director, FTI Consulting

Aspen Medical Collaborates with University of Wollongong in Dubai to Strengthen Healthcare Training Initiatives

Aspen Medical, a global leader in healthcare solutions, and the University of Wollongong in Dubai (UOWD) have agreed to work collaboratively to help boost healthcare education, training, and workforce development in the region.

Through a Memorandum of Understanding (MoU) signed by Glenn Keys, Executive Chairman of Aspen Medical, and Professor Mohamed Salem, President of UOWD, the collaboration exemplifies the commitment of both brands to address the growing needs of the healthcare sector through innovative and practical initiatives that benefit students, professionals, and the wider community.

As part of the collaboration, Aspen Medical and UOWD will jointly deliver healthcare training programs focused on critical care, emergency response, and public health initiatives. Additionally, Aspen Medical and UOWD will collaborate on public health campaigns to promote health awareness and address regional healthcare challenges.

A key feature of the initiative will be the creation of a clinical skills and simulation lab that will further enhance UOWD's learning environment and equip students with hands-on, experiential training in clinical competencies and critical thinking.

"We are excited at the prospect of working with UOWD to create meaningful pathways for students and professionals to advance their skills in healthcare," Keys said. "This collaboration will not only enhance learning experiences but also contribute to workforce development and emergency preparedness in the region."

"Collaborating with Aspen Medical opens doors to innovative healthcare education and training opportunities," Professor Salem commented. "Our students will greatly benefit from the hands-on experiences and real-world insights that Aspen Medical brings to the table. We look forward to working together to address regional healthcare needs through education and outreach."

Claire Westbrook-Keir, General Manager of Aspen Medical in the UAE, remarked on the significance of the initiative: "This collaboration with UOWD is an exciting step forward in our mission to elevate healthcare education and workforce readiness. By combining Aspen Medical's global expertise with UOWD's strong academic foundation, we are confident in the long-term impact this will have on healthcare training and public health awareness in the region."

Aspen Medical will also contribute to UOWD's Health Sciences faculty by offering guest lectures covering field hospital operations, emergency response in high-risk environments, and the latest innovations in deployable healthcare technologies. In addition, Aspen Medical will provide advisory services to help UOWD strengthen healthcare standards and workforce readiness in line with the best global practices. Health Sciences students and alumni will also benefit from internship opportunities at Aspen Medical's remote healthcare facilities and public health campaigns.

The MoU underscores the shared vision of Aspen Medical and UOWD to foster a sustainable healthcare workforce that is equipped to address the evolving challenges of the sector.

Europlaz Introduces Ground breaking Neonatal Innovation

Europlaz, a UK-based leader with over 40 years of expertise in the medical device and life sciences sector, has unveiled a revolutionary neonatal innovation aimed at improving care for premature and distressed newborns. The company's latest advancement integrates a patented 'sidestream' CO2 sampling port into its neonatal flow sensor, enhancing both functionality and clinical outcomes.

This breakthrough design allows clinicians to adhere to critical protocols for lung-protective volume control and CO2 monitoring, significantly improving survival chances while reducing the risk of long-term complications like cerebral palsy and lung disease. By combining the flow volume sensor with a precisely positioned gas sampling port for tidal flow CO2 monitoring, the innovation minimizes 'dead space' and ensures more accurate readings compared to existing products.

Developed at Europlaz's Chelmsford facility, this innovation is gaining traction among ventilator manufacturers. Two global companies have already adopted the new sensor, and clinical trials are set to commence at a leading London hospital. These trials aim to provide the robust evidence needed to further encourage adoption across the healthcare sector.

Europlaz is also scaling up its production capabilities to meet growing demand. A state-of-the-art robotic welder is being integrated into its modern production cell, featuring vision-controlled micro-robotic wire welding technology. This equipment ensures exceptional sensor quality and reliability, with precision welding of materials thinner than

a human hair.

Frede Jensen, Europlaz's Product Development Manager with extensive experience in neonatal technologies, expressed confidence in the innovation's potential: "This equipment is a game-changer, allowing us to deliver consistent and precise products. Our goal is to make a tangible difference in neonatal care, saving lives and reducing healthcare costs."

Europlaz's commitment to advancing neonatal care demonstrates its dedication to driving impactful innovations in the medical field.

Hikma Secures Rights to a Portfolio of Takeda Brands for the MENA Region

Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, has agreed with Takeda Pharmaceuticals International AG (Takeda) to acquire the rights to 17 brands currently licensed to Hikma for select territories in the Middle East and North Africa (MENA) region.

Through a number of licensing contracts, the latest of which was entered into in 2017, Hikma developed a strategic partnership with Takeda to license, commercialize and, in some cases, manufacture a portfolio of products in the MENA region. Today the portfolio includes attractive and growing branded products used for cardiovascular, diabetes, gastroenterology and pain management.

Hikma has now agreed with Takeda that it will acquire the rights to these marketed brands. Hikma will continue to commercialize all 17 brands and will, over time, move the manufacture of these products in-house. This will ensure the continuity of supply of these important medicines, which are widely used by patients across the region. The acquisition will result in improved efficiency and cost saving opportunities, which will support the profitability of the Branded business.

Mazen Darwazah, Hikma's Executive Vice Chairman and President of MENA said: "We have been successfully commercializing

this portfolio of products across the region for a number of years, supported by our highly-specialized sales and marketing team with strong local market expertise. By bringing these products in-house, we will not only ensure an uninterrupted supply of products to our customers but will also have better control of our supply chain, which will result in cost saving opportunities over the medium term. We are confident this acquisition will strengthen our Branded business and reinforce our commitment to provide high-quality medicines to patients in MENA.

Abu Dhabi Precision Medicine Programme Supports 256 Emirati Cancer Patients with Tailored Treatment Plans

Since the launch of the region's first Personalized Precision Medicine Programme for Oncology in October 2022, the Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, together with strategic partners, has offered tailored treatment plans to 256 Emirati cancer patients in Abu Dhabi and personalized prevention plans.

As part of the programme, a select group of cancer patients received personalized treatment and prevention plans from genetic counsellors and specialists to enhance treatment efficiency and recovery. Eligible patients underwent screening for 47 genes to improve their clinical care. To mitigate tumor development risk, the programme tailored preventive plans for 207 family members of patients who tested positive for inherited gene mutations

linked to specific cancers. This proactive approach ensures the implementation of effective measures to lower cancer risk in future generations.

Furthermore, as part of the programme, 200 additional patients aged between 25 and 50 years old have been randomly selected from the Emirati Genome Programme (EGP) to test for gene variants that put them at higher risk of developing breast, ovarian, colorectal and lung cancer. Those identified as high-risk received tailored prevention plans. Additionally, high-risk asymptomatic individuals were directed to specialized clinics for close monitoring, intervention and lifestyle modifications.

In line with its commitment to advancing oncology care, DoH recently released guidelines for germline testing of breast and ovarian cancer-associated genes to improve diagnosis, treatment, and prevention approaches.

Launched by DoH in collaboration with Cleveland Clinic Abu Dhabi, and G42 Healthcare in 2022, the Personalized Precision Medicine Programme for Oncology in the region aims to enhance genomic screening, disease prevention, diagnostic processes, and advanced therapeutic decision-making for breast cancer patients. In addition to reducing the risk or recurrence of the disease, the programme builds on DoH's mission to drive the future of the healthcare sector with breakthrough technologies and position Abu Dhabi as an innovation hub for life sciences.

LPE Expands Capacity with Second Axtra3D Lumia X1 for Medical Device Manufacturing

LPE, a prominent name in additive manufacturing, has announced the integration of a second Axtra3D Lumia X1 printer into its operations during Formnext 2024. This achievement positions LPE as the first company globally to operate two of these state-of-the-art machines, underlining its commitment to staying at the forefront of innovation.

The investment responds to the increasing demand from industries such as healthcare, aerospace, and motorsport, where precision, reliability, and efficiency are paramount. By doubling its Axtra3D Lumia X1 capacity, LPE aims to significantly reduce production lead times while enhancing its ability to handle complex projects.

The Axtra3D Lumia X1 incorporates the advanced Hybrid PhotoSynthesis (HPS) technology, combining the strengths of stereolithography (SLA) and digital light processing (DLP). This technology delivers exceptional precision, speed, and material versatility, resulting in parts with near-isotropic mechanical properties and consistent performance across all axes. This strategic expansion reinforces LPE's ability to address the demanding needs of healthcare clients. The company's material offerings include biocompatible, chemical-resistant, and sterilizable polymers, essential for manufacturing medical devices that meet stringent regulatory and safety standards. Moreover, LPE's materials portfolio supports the production of ESD-compliant parts for sensitive electronic applications, ensuring versatility from prototyping to low-volume production.



Siemens Healthineers Appoints Vivek Kanade as New Head for its Middle East and Africa Operations

Siemens Healthineers, one of the world's leading medical technology companies, announced the appointment of Vivek Kanade as the new Head for the company's business/operations in the Middle East and Africa (MEA). The appointment, effective 4 December 2023, follows the company's decision to unite its operations across the Middle East and the African continent with the aim to better serve the diverse needs of healthcare providers and communities.

Kanade is a Siemens veteran bringing more than thirty years of experience in the company from across different geographies and functions. In his previous role, Kanade held the position of Head of Strategy for the company's expansive Asia Pacific Japan region, prior to which Kanade was the Head at Siemens Healthineers for India, Bangladesh, Nepal, Sri Lanka, Bhutan and the Maldives. During this time, he was also Co-Chair at NatHealth in India, actively advising the Indian medical technology industry.

Commenting on the appointment, Vivek Kanade said: "As we strengthen our role as a trusted healthcare partner in this diverse growth region, this structural consolidation enables us to pool our strengths in following our core objectives, which include enhancing Access to Care and paving the way for better healthcare infrastructures in our markets. I am humbled and excited to start this new position, and look forward to uniting our strengths across the new zone and creating a positive difference in the lives of millions of patients across the Middle East and Africa."

In his current capacity, Kanade has a vision to create an even bigger impact on patient's lives, increasing patient touchpoints and leveraging the diverse opportunities in economically challenging growth markets of Africa and the Middle East.

Part of this vision and a strong focus area will be Access to Care, a Siemens Healthineers initiative structured around providing healthcare to everybody, everywhere. The initiative entails improvement of healthcare infrastructure, tackling the shortage of qualified staff and availability of healthcare provision for rural and underserved communities to making a lasting impact where it is needed the most.

"We aspire to create better outcomes and experiences for patients, no matter where they live by accelerating global development, building strategic partnerships, fighting the most threatening diseases, and rethinking the value chain," added Kanade. "Specifically, we're focusing on projects that are first and foremost scalable and fit our strategy while making an impact on local communities, by untapping new markets, capacity building and ensuring community reach."

Meril Launches Myval Octapro THV at GISE & PCR 2024

Meril Life Sciences, a leading global med-tech company specializing in cardiovascular and structural heart solutions, marked a significant milestone with the launch of its Myval Octapro Transcatheter Heart Valve (THV) at GISE 2024 (National Congress of the Italian Society of Interventional Cardiology) and PCR London Valves 2024. These esteemed scientific events provided an ideal platform for Meril to showcase its commitment to advancing structural heart care.

The Myval THV series, known for its innovative contributions to transcatheter aortic valve replacement (TAVR) procedures, continues to set new benchmarks with the Myval Octapro THV. This latest iteration introduces low frame foreshortening, enhancing operator control and enabling precise deployment for improved procedural predictability. Additionally, its comprehensive size matrix, which includes conventional, intermediate, and extra-large valve sizes, ensures optimal valve selection tailored to diverse patient anatomies.

Dr Ashok Seth of Fortis Escorts Heart Institute and D Rajneesh Kapoor of Medanta emphasized the significance of these innovations in improving patient outcomes.

At PCR London Valves 2024, Meril presented key findings from the LANDMARK trial subset analysis and comparative studies, further establishing the safety and efficacy of the Myval Transcatheter Heart Valve (THV) series. Published in EuroIntervention Journal, the findings confirmed the Myval THV's non-inferiority to both Sapien and Evolut valve series at 30 days post-implantation, solidifying its position as a reliable solution for structural heart interventions.



UPCOMING EVENTS

MEDIWORLD Middle East

3rd January 2025 — **Dubai**
International Conference on Plastic and Aesthetic Surgery

7th January 2025 — **Dubai**
Dubai International Pharmaceutical & Technologies Conference & Exhibition (DUPHAT)

27th January 2025 — **Dubai**
Arab Health

3rd February 2025 — **Dubai**
Medlab Middle East

24th February 2025 — **Jeddah, KSA**
Saudi Healthcare Transformation Summit

12th March 2025 — **London, UK**
Pharma Supply Chain & Security World 2025

14th April 2025 — **Dubai**
Dubai Derma 2025

15th April 2025 — **Abudhabi**
Abu Dhabi Global Health Week

17th April 2025 — **Abudhabi**
MENA Congress for Rare Diseases 2025

HI-CARE
PROTECTION
Feels Good

- WHO Recommended Formulation [2]
- kills 99.99% of bacteria [4]
- Effective against viruses [5]
- Quick Dry
- Non Sticky
- Soft On Hands [2]
- 80% Ethanol [1]
- Multipurpose [3,5]
- For Surfaces

medpharma
Pharma. & Chem. Ind's (L.L.C.)
P.O.Box:25235, Ind.Area No:13, Street No:37, Sharjah, U.A.E.
Subsidiary of Bausch Health Companies Inc.

References: 1. Data on file – Hi-Care Alcohol Antiseptic 80% Topical Solution Composition Formula. 2. World Health Organization - Guide to Local Production: WHO-recommended Handrub Formulations. April 2010. 3. FDA Policy for Temporary Compounding of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency Immediately in Effect Guidance for Industry. March 2020. 4. Data on file – Dubai Central Laboratory Report No: CR-600076509, 01/07/2020. 5. Nina A. Gold ; Taaha M. Mirza ; Usha Avva, Alcohol Sanitizer, NCBI Bookshelf, StatPearls Publishing; January 2020.
HI/MVE/1220 - 6MVBS3BI-150421

#محمي_و_مبسوط
#protection_feels_good